Multiple Ascending Dose (MDX1105-01)

Completed · Phase 1

Conditions studied: Cancer, Multiple Indications

In brief

Collection of survival data, evaluation of PDL-1 expression in tumors, and evaluation of PD-L1 receptor occupancy in peripheral blood has been added.

Key facts

Study ID

NCT00729664

Run by

Bristol-Myers Squibb

People needed

281

Starts

2009-02-01

Expected to finish

2015-07-01

Last updated by the study team

2015-09-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 1
• The malignancies include relapsed/refractory renal cell carcinoma, non-small cell lung cancer, colorectal adenocarcinoma, malignant melanoma, advanced/metastatic epithelial ovarian cancer, gastric cancer, pancreatic cancer and breastcancer
• Must have measurable disease

You may not qualify if…

• Prior therapy with an anti-PD 1, anti-PDL 1, or anti-Cytotoxic T-Lymphocyte Antigen 4 antibody (or any other agents that target T-cell co-stimulation)

Where it is running

• The Angeles Clinic & Research Institute — Los Angeles, California, United States
• Emory University — Atlanta, Georgia, United States
• University Of Chicago — Chicago, Illinois, United States
• Johns Hopkins University — Baltimore, Maryland, United States
• Mayo Clinic — Rochester, Minnesota, United States
• Roswell Park Cancer Institute — Buffalo, New York, United States
• University Of Cincinnati — Cincinnati, Ohio, United States
• Ohio State University — Columbus, Ohio, United States
• Oncology Consultants, Pa — Houston, Texas, United States
• The University Of Texas — Houston, Texas, United States
• Fred Hutchinson Cancer Center — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.